See inside every stock. Pro
S&P 5007,723▲ 0.60%Nasdaq26,478▲ 1.18%Dow Jones52,378▲ 0.03%Nasdaq 10029,651▲ 1.29%VIX17.52▼ 4.73%US Dollar102.35▲ 0.39%Gold spot4,006▲ 0.30%WTI101.38▲ 1.48%
← GALD page
XStocksXray
Market X-Ray report · 27 October 2026

Galderma Group N (GALD)

SIX Swiss Exchange · Switzerland · prices in CHF · close of 27 Oct 2026

Key indicators

Last closeCHF 185.00
52-week range136.30 – 193.90
Return, 1 month / 3 months+13.5% / +6.6%
Return, 1 year / 3 years+32.7% / –
TrendUptrend
RSI (14)67
Volatility (1 year)29.1%
Worst drawdown (1 year)-17.5%
Average daily value traded100.16M CHF
Dividend yield0.2%

Market X-Ray price-based

65/ 100 · High confidence · ahead of 77% of stocks on this exchange
Trend71
Momentum66
Stability (higher is calmer)63
Liquidity97
Income3

Five-year price chart navy: price · brown: 200-day average

44.5083.211221611992024-032024-112025-072026-032026-10

About the company

Galderma is a dermatology company that develops and markets skin health products. Its range covers prescription medicines for skin conditions, injectable treatments used in aesthetic medicine, and everyday skincare brands sold to consumers. The company serves dermatologists, other healthcare professionals and retail customers, and it is based in Switzerland. Its products reach patients and consumers through pharmacies, clinics and retail channels in many countries.

Galderma Group N trades under the code GALD on the SIX Swiss Exchange in Switzerland, with its price quoted in Swiss francs (CHF). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

Summary

Galderma Group N (GALD) trades on the SIX Swiss Exchange in Switzerland. It last closed at CHF 185.00 on 27 October 2026.

Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 53 of 226 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.

Over the last year the price rose 32.7% and over the last three months it rose 6.6%. Returns are price returns, dividends not included.

Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.

stocksxray.com · page 1
XStocksXray
Galderma Group N (GALD)

The five lenses in numbers each metric is ranked against the other stocks on SIX Swiss Exchange

Lens and metricValueScoreReading
Trend71 · StrongTrading above its long-term averages and near its highs.
Above 200-day average14.0%
From 52-week high-3.2%
Momentum66 · FairTypical recent returns for this exchange.
3-month return6.6%
6-month return13.2%
12-month return, skipping the last month16.9%
Stability (higher is calmer)63 · FairTypical risk for this exchange.
Volatility, 1 year (lower is calmer)29.1%
Worst drawdown, 1 year (smaller is calmer)-17.5%
Liquidity97 · StrongTrades actively.
Average daily value traded100.16M CHF
Zero-volume days0.0%
Income3 · WeakDividend is small or irregular.
Dividend yield0.2%
Years with dividends2

Strengths

  • Trend: Trading above its long-term averages and near its highs.
  • Liquidity: Trades actively.

Weak spots

  • Income: Dividend is small or irregular.

Returns

1 week+5.7%
1 month+13.5%
3 months+6.6%
6 months+13.2%
1 year+32.7%
3 years–
5 years–

Signals

50-day / 200-day average166.50 / 162.32
Golden / death cross (60 days)None
New 52-week highYes
Bullish RSI divergenceNo
Average daily range (ATR)4.98

Technical summary

DailyStrongly bullish12 bullish · 3 neutral · 1 bearish
WeeklyStrongly bullish9 bullish · 1 neutral · 0 bearish
MonthlyStrongly bullish4 bullish · 0 neutral · 1 bearish

Recent dividends

Ex-dividend dateAmount per share
24 Apr 2026CHF 0.3500
25 Apr 2025CHF 0.1500

How to read this report

Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on SIX Swiss Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.

stocksxray.com · page 2 · generated 28 Oct 2026